Lack Of Facts Dooms Class Cert Over Takeda Gout Drug

By Bryan Koenig · November 28, 2022, 9:16 PM EST

A federal judge last week rejected a bid by pharmacy chain Value Drug Co. to certify a class of roughly 50 purchasers of Takeda Pharmaceuticals' anti-gout drug Colcrys alleging that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2021

Recent Articles By Bryan

November 15, 2024
PBMs Denied Breakup Of Combined FTC Insulin Price Trial
November 13, 2024
Outgoing DOJ Antitrust Head Wants To Unstack Healthcare
November 12, 2024
HIV Drug Buyers Want Gilead Product Switch Claims Revived
November 12, 2024
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
November 07, 2024
Same PBM Conduct Means Same Insulin Price Trial, FTC Says
October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
September 06, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified